TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004933
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 to 5 grams PO per day
Study: NCT00004933
Drug: Homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/ sq m/ day CIVI for 14 days
Study: NCT01430533
Drug: azelaic acid pre foam formulation
Normalized name: azelaic acid Topical Foam
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01430533
Drug: Water
Normalized name: Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890329
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02420353
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
Study: NCT01293097
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Study: NCT04138251
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral administration of Empagliflozin
Study: NCT01159145
Drug: D961H
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, capsule
Study: NCT01159145
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, tablet
Study: NCT03169816
Drug: Lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorcaserin 10mg, twice daily
Study: NCT00930215
Drug: D961H
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral gelatin capsule
Study: NCT00930215
Drug: D961H
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral HPMC capsule
Study: NCT01149057
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg intravenously, every 4 weeks for 96 weeks
Study: NCT03905967
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
Study: NCT03602339
Drug: Gadoterate (Dotarem/Clariscan)
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
Study: NCT03602339
Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
Study: NCT01140672
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
Study: NCT03630627
Drug: SB26
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB26 administered intravenously
Study: NCT02206568
Drug: URAL
Normalized name: Curaler
DrugBank: Nitrofural (DB00336)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01652898
Drug: ONO LDL50
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study: NCT01652898
Drug: Esmolol hydrochloride
Normalized name: Esmolol Hydrochloride
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Study: NCT04275115
Drug: Foliglurax
Normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foliglurax
Study: NCT04275115
Drug: midazolam iv
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single intravenous (iv) dose of midazolam 0.025 mg/kg
Study: NCT00955994
Drug: asimadoline
Normalized name: Asimadoline
DrugBank: Asimadoline (DB05104)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01140672
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
Study: NCT01140672
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
Study: NCT01140672
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
Study: NCT01140672
Drug: PF-04634817
Normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
Study: NCT02761915
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02294305
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01868243
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 - Dabigatran 110 mg (50 patients)
Study: NCT01868243
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin adjusted-dose
Study: NCT03354338
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
Study: NCT02824510
Drug: Insulin aspart, glargine and detemir
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02775994
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: interleukin beta (IL-1) antagonist
Study: NCT02957877
Drug: Nadroparin
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
Study: NCT02899156
Drug: Flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01874535
Drug: Esomeprazole 40 mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
Study: NCT03961360
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
Study: NCT03573544
Drug: OBI-888
Normalized name: OBI-888
DrugBank: OBI-888 (DB18289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
Study: NCT03573544
Drug: OBI-888
Normalized name: OBI-888
DrugBank: OBI-888 (DB18289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
Study: NCT00096655
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04371224
Drug: Irinotecan Liposomal Injection [Onivyde]
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: both arm
Study: NCT04371224
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NAPOLI
Study: NCT04481451
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine 0.2% nerve block injection
Study: NCT02957877
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
Study: NCT00227370
Drug: valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: valgan 900mg QD x 9 months post lung transplant
Study: NCT00983996
Drug: Alendronate Sodium Tablets, 10 mg
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg, single-dose fasting
Study: NCT03961360
Drug: Aspirin 162 mg
Normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
Study: NCT01493180
Drug: Sodium hyaluronate ophthalmic solution
Normalized name: sodium hyaluronate Ophthalmic Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hyaluronate ophthalmic solution 0.1%
Study: NCT00218465
Drug: GW468816
DrugBank: GW 468816 (DB05417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapies for Relapse Prevention
Study: NCT04241965
Drug: OPC-214870
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s)
Study: NCT03051945
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
Study: NCT02674529
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI)
Study: NCT02891850
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
Study: NCT02891850
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Study: NCT02891850
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Study: NCT03566394
Drug: Gabapentin 300mg
Normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
Study: NCT01821521
Drug: AGSPT_L20
Normalized name: OCTINOXATE 7.5 g in 100 g / TITANIUM DIOXIDE 5.02 g in 100 g TOPICAL LIQUID [Sheer Defense Tinted Moisturizer SPF15 L20 Merle Norman]
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01821521
Drug: Pantoloc 40mg
Normalized name: Pantol
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00963196
Drug: Bovine gelatin capsules
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine gelatin capsules that appear similar to active drug acting as placebo.
Study: NCT03506178
Drug: Oxymetazoline Nasal Spray
Normalized name: oxymetazoline Nasal Spray
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study: NCT03506178
Drug: Menthol Nasal Spray
Normalized name: PHENYLEPHRINE 0.5%/MENTHOL NASAL SPRAY
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Study: NCT01261767
Drug: anti-IL-20
Normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
Study: NCT02397278
Drug: Platelet rich plasma (PRP)
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
Study: NCT03759704
Drug: Hyperpolarized 13CPyruvate
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of study drug during MRSI.
Study: NCT01693653
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusions every 4 weeks for 3 doses.
Study: NCT01244724
Drug: Lexapro
Normalized name: Lexapro
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
Study: NCT02050529
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
Study: NCT02050529
Drug: Hydralazine
Normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
Study: NCT02638545
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
Study: NCT02721563
Drug: Sodium Glycididazole
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
Study: NCT01120028
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Study: NCT01120028
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg intravenously, two doses 96 hours apart
Study: NCT01120028
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
Study: NCT01120028
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Study: NCT03694535
Drug: bladder wall thermotherapy with Mitomycin-c
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: application of intravesical mitomycin-C with hyperthermia
Study: NCT02291796
Drug: Bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
Study: NCT03033433
Drug: DCB-DM101
Normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: determination of optimal dose for Stage 2
Study: NCT01502904
Drug: pitavastatin 2mg/day after DES implantation
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Study: NCT01653041
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00654498
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04062175
Drug: cephalosporin
Normalized name: Cephalosporin
DrugBank: Cephalosporin analog (DB02136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
Study: NCT02531906
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02531906
Drug: Methadone Hydrochloride
Normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02531906
Drug: Oxycodone Hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01401062
Drug: Fresolimumab
Normalized name: Fresolimumab
DrugBank: Fresolimumab (DB12396)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00963547
Drug: MK-2206
Normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
Study: NCT00963547
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
Study: NCT03504475
Drug: Paroxetine Hydrochloride Tablet 20 mg
Normalized name: paroxetine hydrochloride Oral Tablet
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
Study: NCT04980040
Drug: Alogliptin Benzoate
Normalized name: Alogliptin Benzoate
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin benzoate tablets
Study: NCT01332474
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BOTOX
Study: NCT04362293
Drug: hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor.